Across 247,316 continuous glucose monitoring days from 716 Apple Women's Health Study participants, women with polyendocrine metabolic ovarian syndrome (PMOS, the newer name for PCOS) averaged 6.81 mg/dL higher glucose than women with regular cycles, and spent 3.77% more time above target range. Women with early-life irregular cycles but no PMOS showed smaller shifts, while PMOS with androgen excess showed larger ones. Meeting activity goals, eating protein- and fiber-rich diets, and using metformin or GLP-1 receptor agonists attenuated the gaps.
The real-world, free-living data are a strength, since most PMOS glycemic research relies on clinic-based glucose tolerance tests. But the caution is considerable. The mean glucose estimate's confidence interval (-0.70 to 14.72) crosses zero, so only the time-above-range result reached nominal significance, and its lower bound sits at 0.04. Participants are self-selected Apple Watch users who chose to wear CGMs, probably healthier and more engaged than typical patients, and many may not have diabetes. The effect-modifier findings are observational: women who exercise or take metformin differ in many other ways, and treatment indication confounds medication comparisons. Same-day diet and activity logs cannot show lasting benefit. This is a preprint that has not been peer reviewed, and results may change. It is best read as confirmatory: it fits what is known about insulin resistance in PMOS and supports exercise, fiber and protein as sensible first-line habits, while adding little new proof that they prevent diabetes.